Sichuan Kelun-Biotech Biopharm (6990.HK) Placement - Thoughts The Pipeline and Valuation Outlook
​Kelun Bio's HK$331.8/share Placing price is expensive.Valuation should be higher than Akeso.Buy when valuation falls in US$2.5-5.25 billion...
510 Views
ECM Weekly (9 June 2025) - Haitian, Sanhua, Virgin Aus, Primo, Kitazato, Wistron, Kelun Bio, Mao Gep
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
635 Views
Kelun-Biotech Placement - Recent Run-Up Makes Its Tricky
Kelun-Biotech Biopharmaceutical Co (Kelun) is looking to raise up to US$200m from a primary placement. In this note, we will talk about the...
523 Views
China Healthcare Weekly (Jun.1)-Akeso/Summit's Disappointing Ph3 Readout,Valuation Outlook of Biokin
​CR Sanjiu plans to transfer 49.8967% equity of Sanjiu (Anguo).Summit/Akeso's disappointing phase 3 readout raises doubts on FDA approval for...
513 Views
Pre-IPO Xuanzhu Biopharmaceutical- Outdated Pipelines Are Difficult to Bring Good Investment Returns
​Sihuan's acquisition of Combio aims to create a strong innovative drug business Xuanzhu, but concerns arise over its outdated pipeline,...
425 Views